This week, James is joined by Geoff von Maltzahn, CEO and co-founder at Tessera Therapeutics. Tessera is an early-stage biotech start-up that launched this summer with $50M in financing to pioneer a new category in ‘gene writing.’ Going even further than CRISPR, Tessera’s gene writing technology presents the potential to cure genetic disorders, cancers, and even infectious diseases like COVID-19. Geoffrey was awarded a Ph.D. in biomedical engineering and medical physics from MIT.
Get in touch with Geoff: @GVMaltzahn | https://www.linkedin.com/in/geoffrey-von-maltzahn-7a6b755a/
Subscribe to Healthtech Pigeon 🐦www.healthtechpigeon.com
Get in touch: www.jamessomauroo.com | www.somx.co.uk
The Healthtech Podcast